stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Revenue
Legend Biotech Corporation Sponsored ADR's revenue for fiscal 2025 was $1.0B, up 64.0% from $627.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.3B. Over the past ten years it has ranged from $23.6M (fiscal 2017) to $1.0B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Legend Biotech Corporation Sponsored ADR ranks 19th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.0B | 64.02% |
| FY2024 | $627.3M | 119.99% |
| FY2023 | $285.1M | 143.70% |
| FY2022 | $117.0M | 70.00% |
| FY2021 | $68.8M | (15.86%) |
| FY2020 | $81.8M | 27.03% |
| FY2019 | $64.4M | 2.15% |
| FY2018 | $63.0M | 167.16% |
| FY2017 | $23.6M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $387.5M | 27.01% |
| Mar 2026 | $305.1M | (0.45%) |
| Dec 2025 | $306.5M | 12.54% |
| Sep 2025 | $272.3M | 6.75% |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR | $1.3B |
| TVTX Travere Therapeutics, Inc. compare | $651.0M |
| CRSP CRISPR Therapeutics AG compare | $25.2M |
| COGT Cogent Biosciences, Inc. compare | $23.2M |
| RLAY Relay Therapeutics, Inc. compare | $11.0M |
| DNTH Dianthus Therapeutics, Inc. compare | $2.7M |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LEGN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement